幽门螺旋杆菌根除后患者的益生菌混合物:现实生活中的经验。

IF 1.9 Q3 GASTROENTEROLOGY & HEPATOLOGY Minerva gastroenterology Pub Date : 2024-06-01 Epub Date: 2024-03-26 DOI:10.23736/S2724-5985.24.03634-9
Salvatore E Aragona, Carlo Fabbri, Giovanni Cammarota, Giorgio Ciprandi
{"title":"幽门螺旋杆菌根除后患者的益生菌混合物:现实生活中的经验。","authors":"Salvatore E Aragona, Carlo Fabbri, Giovanni Cammarota, Giorgio Ciprandi","doi":"10.23736/S2724-5985.24.03634-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Eradication for Helicobacter pylori usually induces digestive dysbiosis that, in turn, elicits symptoms. Consequently, probiotic supplementation may counterbalance the disturbed microbiota after this procedure. So, probiotics may restore microbiota homeostasis quickly relieve complaints.</p><p><strong>Methods: </strong>The current study evaluated the efficacy and safety of Abivisor<sup>®</sup>, a food supplement containing Lacticaseibacillus rhamnosus LR06 (3 billion living cells), Lactiplantibacillus pentosus LPS01(100 million living cells), Lactiplantibacillus plantarum LP01 (1 billion living cells), and N-acetyl cysteine (60 mg). Patients were randomized into two groups (2:1). Group A took one stick/daily for 60 days after eradication. Group B was considered as control. Patients were evaluated at baseline (T0) and after 15 (T1), 30 (T2), and 60 (T3) days. The severity of digestive symptoms was measured by patients using a Visual Analog Scale. The percentage of patients with each symptom was also evaluated.</p><p><strong>Results: </strong>Abivisor<sup>®</sup> has significantly and progressively diminished intestinal symptoms' presence and severity at T1, T2, and even more at T3. Accordingly, the percentage of symptomatic patients diminished more rapidly and significantly in group A than in B. All patients well tolerated the food supplement.</p><p><strong>Conclusions: </strong>The present study suggests that Abivisor<sup>®</sup> may be an effective and safe therapeutic option for managing patients undergoing H. pylori eradication.</p>","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"197-207"},"PeriodicalIF":1.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Probiotic mixture in patients after Helicobacter pylori eradication: a real-life experience.\",\"authors\":\"Salvatore E Aragona, Carlo Fabbri, Giovanni Cammarota, Giorgio Ciprandi\",\"doi\":\"10.23736/S2724-5985.24.03634-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Eradication for Helicobacter pylori usually induces digestive dysbiosis that, in turn, elicits symptoms. Consequently, probiotic supplementation may counterbalance the disturbed microbiota after this procedure. So, probiotics may restore microbiota homeostasis quickly relieve complaints.</p><p><strong>Methods: </strong>The current study evaluated the efficacy and safety of Abivisor<sup>®</sup>, a food supplement containing Lacticaseibacillus rhamnosus LR06 (3 billion living cells), Lactiplantibacillus pentosus LPS01(100 million living cells), Lactiplantibacillus plantarum LP01 (1 billion living cells), and N-acetyl cysteine (60 mg). Patients were randomized into two groups (2:1). Group A took one stick/daily for 60 days after eradication. Group B was considered as control. Patients were evaluated at baseline (T0) and after 15 (T1), 30 (T2), and 60 (T3) days. The severity of digestive symptoms was measured by patients using a Visual Analog Scale. The percentage of patients with each symptom was also evaluated.</p><p><strong>Results: </strong>Abivisor<sup>®</sup> has significantly and progressively diminished intestinal symptoms' presence and severity at T1, T2, and even more at T3. Accordingly, the percentage of symptomatic patients diminished more rapidly and significantly in group A than in B. All patients well tolerated the food supplement.</p><p><strong>Conclusions: </strong>The present study suggests that Abivisor<sup>®</sup> may be an effective and safe therapeutic option for managing patients undergoing H. pylori eradication.</p>\",\"PeriodicalId\":94142,\"journal\":{\"name\":\"Minerva gastroenterology\",\"volume\":\" \",\"pages\":\"197-207\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/S2724-5985.24.03634-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-5985.24.03634-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:根除幽门螺杆菌通常会引起消化道菌群失调,进而引发各种症状。因此,补充益生菌可平衡手术后紊乱的微生物群。因此,益生菌可迅速恢复微生物群平衡,缓解症状:本研究评估了 Abivisor® 的有效性和安全性,这是一种含有鼠李糖乳杆菌 LR06(30 亿活细胞)、戊糖乳杆菌 LPS01(1 亿活细胞)、植物乳杆菌 LP01(10 亿活细胞)和 N-乙酰半胱氨酸(60 毫克)的食品补充剂。患者被随机分为两组(2:1)。A 组在根除后 60 天内每天服用 1 支。B 组为对照组。在基线(T0)、15 天(T1)、30 天(T2)和 60 天(T3)后对患者进行评估。患者使用视觉模拟量表测量消化道症状的严重程度。此外,还评估了出现各种症状的患者比例:结果:Abivisor® 在 T1、T2 和 T3 天显著并逐渐减轻了肠道症状的出现和严重程度,在 T3 天的减轻幅度更大。因此,与 B 组相比,A 组有症状患者的比例减少得更快更明显:本研究表明,Abivisor® 是根除幽门螺杆菌患者的一种有效而安全的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Probiotic mixture in patients after Helicobacter pylori eradication: a real-life experience.

Background: Eradication for Helicobacter pylori usually induces digestive dysbiosis that, in turn, elicits symptoms. Consequently, probiotic supplementation may counterbalance the disturbed microbiota after this procedure. So, probiotics may restore microbiota homeostasis quickly relieve complaints.

Methods: The current study evaluated the efficacy and safety of Abivisor®, a food supplement containing Lacticaseibacillus rhamnosus LR06 (3 billion living cells), Lactiplantibacillus pentosus LPS01(100 million living cells), Lactiplantibacillus plantarum LP01 (1 billion living cells), and N-acetyl cysteine (60 mg). Patients were randomized into two groups (2:1). Group A took one stick/daily for 60 days after eradication. Group B was considered as control. Patients were evaluated at baseline (T0) and after 15 (T1), 30 (T2), and 60 (T3) days. The severity of digestive symptoms was measured by patients using a Visual Analog Scale. The percentage of patients with each symptom was also evaluated.

Results: Abivisor® has significantly and progressively diminished intestinal symptoms' presence and severity at T1, T2, and even more at T3. Accordingly, the percentage of symptomatic patients diminished more rapidly and significantly in group A than in B. All patients well tolerated the food supplement.

Conclusions: The present study suggests that Abivisor® may be an effective and safe therapeutic option for managing patients undergoing H. pylori eradication.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
0
期刊最新文献
Application of artificial intelligence combined with MDT teaching model in colorectal cancer training teaching. Pancreatic necrosis: a scoping review. Evaluation of the effect of moxibustion therapy combined with press needle stimulation of bilateral Zusanli (ST36) and Neiguan (PC6) points on gastric motility recovery in patients with gastroparesis after pancreatoduodenectomy. Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected. The role and mechanisms of long non-coding RNA HOTAIR in regulating the Wnt/β-catenin signaling pathway in gastric cancer cells and its impact on tumor invasion and metastasis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1